Vagal reflex actions of atrial natriuretic peptide survive physiological but not pathological cardiac hypertrophy in rat
Why the study?
Does ANP infusion improve vagal baroreflex gain in rats with physiological versus pathological cardiac hypertrophy?
Population
30 conscious, chronically instrumented rats, including those with pathophysiological cardiac hypertrophy…
Comparison
Infusion of Atrial natriuretic peptide at 50… vs Vehicle infusion
Design
Preclinical
Authors
Discussion
Loading...
Member takes
Implication
Hypertrophy etiology dictates ANP baroreflex preservation in rats; extends mechanistic insights but leaves open human translation.
Structured PICO
Does ANP infusion improve vagal baroreflex gain in rats with physiological versus pathological cardiac hypertrophy?
P
Population
30 conscious, chronically instrumented rats, including those with pathophysiological cardiac hypertrophy (1K-1C renovascular hypertension, n=6), physiological cardiac hypertrophy (wheel-running exercise, n=7), uninephrectomised controls (n=10), and sedentary controls (n=7).
I
Intervention
Infusion of Atrial natriuretic peptide (ANP) at 50 pmol kg(-1) min(-1)
C
Comparator
Vehicle infusion
O
Outcome
Cardiac baroreceptor-activated bradycardia (vagal baroreflex gain) measured during rapid ramp increases in blood pressuresurrogate
The etiology of cardiac hypertrophy determines whether atrial natriuretic peptide retains its vagal baroreflex-enhancing properties, with preservation in physiological but not pathological hypertrophy.
Cite This Study
Hood et al. (2004) studied this question.